Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povidone-Iodine effect on nasal cilia in rhinoplasty
NCT04457765Phase 1Withdrawn
- Sponsor
- Boston Medical Center
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of povidone-iodine in Coronavirus Disease 2019 (COVID-19), sponsored by Boston Medical Center. Primary endpoint: Nasal Mucosa Cilia function at 5 weeks. Planned start Apr 2021; status: withdrawn.
02
Drugs
povidone-iodine
03
Conditions
Coronavirus Disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04457765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457765.